Like many ongoing studies, our randomized, double-blind, sham-controlled SCA3-tDCS trial—in which we examine the effects of cerebellar transcranial direct current stimulation (tDCS) in twenty patients with spinocerebellar ataxia type 3 (SCA3)—is affected by the health security measures dictated by the authorities and hospital board [1]. The gene discussed is ATXN3; the disease is Spinocerebellar ataxia type 3.